952 related articles for article (PubMed ID: 31094571)
1. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
2. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501
[TBL] [Abstract][Full Text] [Related]
3. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
4. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate:
Aljaeid BM; El-Say KM; Hosny KM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1130-1139. PubMed ID: 30884977
[No Abstract] [Full Text] [Related]
5. Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro-in vivo studies.
Patil GB; Surana SJ
Artif Cells Nanomed Biotechnol; 2017 May; 45(3):505-514. PubMed ID: 27017892
[TBL] [Abstract][Full Text] [Related]
6. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
7. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Wang X; Chi N; Tang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400
[TBL] [Abstract][Full Text] [Related]
8. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
10. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
11. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery.
Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M
J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502
[TBL] [Abstract][Full Text] [Related]
12. Insulin-loaded mucoadhesive nanoparticles based on mucin-chitosan complexes for oral delivery and diabetes treatment.
Mumuni MA; Kenechukwu FC; Ofokansi KC; Attama AA; Díaz DD
Carbohydr Polym; 2020 Feb; 229():115506. PubMed ID: 31826394
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of insulin chitosan-nanoparticles loaded in buccal films.
Al-Nemrawi NK; Alsharif SSM; Alzoubi KH; Alkhatib RQ
Pharm Dev Technol; 2019 Oct; 24(8):967-974. PubMed ID: 31092092
[TBL] [Abstract][Full Text] [Related]
14. Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting.
Belgamwar A; Khan S; Yeole P
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):374-386. PubMed ID: 28423949
[TBL] [Abstract][Full Text] [Related]
15. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study.
Qureshi M; Aqil M; Imam SS; Ahad A; Sultana Y
Curr Drug Deliv; 2019; 16(2):123-135. PubMed ID: 30317997
[TBL] [Abstract][Full Text] [Related]
16. Preparation of Chitosan Okra Nanoparticles: Optimization and Evaluation as Mucoadhesive Drug Delivery System.
Brar V; Kaur G
Pharm Nanotechnol; 2018; 6(3):180-191. PubMed ID: 30101724
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
[TBL] [Abstract][Full Text] [Related]
18. Understanding the role of colon-specific microparticles based on retrograded starch/pectin in the delivery of chitosan nanoparticles along the gastrointestinal tract.
Dos Santos AM; Meneguin AB; Akhter DT; Fletcher N; Houston ZH; Bell C; Thurecht KJ; Gremião MPD
Eur J Pharm Biopharm; 2021 Jan; 158():371-378. PubMed ID: 33309846
[TBL] [Abstract][Full Text] [Related]
19. Formulation of simvastatin chitosan nanoparticles for controlled delivery in bone regeneration: Optimization using Box-Behnken design, stability and in vivo study.
Delan WK; Zakaria M; Elsaadany B; ElMeshad AN; Mamdouh W; Fares AR
Int J Pharm; 2020 Mar; 577():119038. PubMed ID: 31953085
[TBL] [Abstract][Full Text] [Related]
20. Intranasal delivery of tapentadol hydrochloride-loaded chitosan nanoparticles: formulation, characterisation and its in vivo evaluation.
Javia A; Thakkar H
J Microencapsul; 2017 Nov; 34(7):644-658. PubMed ID: 28862072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
